The CML Channel

Explore the latest updates, including expert interviews, features, podcasts and e-learning
Latest videos Conferences Other Leukemia Subtypes Topics Features

Welcome to The Chronic Myeloid Leukemia (CML) Channel

VJHemOnc brings you the newest advances within the field of CML, with video interviews, podcasts, articles and more. The Chronic Myeloid Leukemia Channel provides coverage from key congresses on the latest developments in CML including therapy updates, managing cardiovascular toxicities and the role of transplantation in CML.

Conferences

ASH 2022
ESH CML 2022
SOHO 2022
EHA 2022
ASCO 2022
BSH 2022
4:23
Phase I study of olverembatinib in patients with R/R CML & Ph+ ALL
Elias Jabbour • 5 Dec 2022
2:49
Outcomes of patients with CML-CP treated with ponatinib vs 2G-TKIs in the third-line setting
Elias Jabbour • 5 Dec 2022
2:32
Outcomes of patients with CML with no molecular response within two years of TKI therapy
Aram Bidikian • 9 Jan 2023
3:05
The role of the immune microenvironment in CML and its impact on patient response to therapy
Aram Bidikian • 9 Jan 2023
View All Videos
2:45
Understanding the cause of TKI resistance to improve management strategies in CML
Jeffrey Lipton • 26 Oct 2022
6:22
Efficacy & tolerability of available TKI therapies in CML & managing TKI resistance
Jeffrey Lipton • 26 Oct 2022
1:24
Ongoing studies in CML: investigating asciminib toxicity and improving TFR rates
Michael Deininger • 21 Oct 2022
1:13
Understanding the mechanisms of resistance to TKIs in CML to help choose better treatment strategies
Camille Kockerols • 21 Oct 2022
View All Videos
3:05
Current and future treatment strategies for blast-phase CML
Mhairi Copland • 29 Sep 2022
1:36
The importance of improving treatment-free remission in patients with CML
Mhairi Copland • 29 Sep 2022
1:12
The challenges associated with long-term TKI use in patients with CML
Mhairi Copland • 29 Sep 2022
2:11
Addressing the issue of resistance to TKIs in CML
Giuseppe Saglio • 28 Oct 2022
View All Videos
5:07
The impact of bariatric surgery on the outcomes of patients with CML treated with TKIs
Fadi Haddad • 24 Jun 2022
1:44
Emerging novel agents for the treatment of mastocytosis
Tracy George • 12 Jun 2022
1:26
The efficacy of nilotinib treatment approaches in frontline CML
Timothy Hughes • 12 Jun 2022
6:41
Factors associated with successful TFR in patients with CML who have discontinued TKI therapy
Fadi Haddad • 24 Jun 2022
View All Videos
1:02
Working towards a cure in CML
Jorge Cortes • 4 Jun 2022
0:55
Managing adverse events associated with TKIs in CML
Jorge Cortes • 4 Jun 2022
2:32
Bosutinib in newly diagnosed CML: GI, liver, effusion, and renal safety characterization
Jorge Cortes • 4 Jun 2022
View All Videos
1:27
European Society of Cardiology: 2022 cardio-oncology guidelines
Alex Lyon • 3 Apr 2022
2:37
Reducing the risk of cardiovascular toxicities when treating hematological malignancies
Alex Lyon • 3 Apr 2022
View All Videos

Topics

Transplant
Immuno-Oncology
Trial Updates
Treatment
Diagnosis
Disease Biology
2:32
Outcomes of patients with CML with no molecular response within two years of TKI therapy
Aram Bidikian • 9 Jan 2023
3:05
The role of the immune microenvironment in CML and its impact on patient response to therapy
Aram Bidikian • 9 Jan 2023
3:20
The current standard of care in CML and insights into the use of first- and second-generation TKIs
Giuseppe Saglio • 25 Oct 2022
0:56
The efficacy of asciminib in patients with CML who are resistant or intolerant to TKI therapy
Camille Kockerols • 21 Oct 2022
View All Videos
2:59
OPTIC 3-year update: dose-optimization of 3 starting doses of ponatinib in CP-CML
Jorge Cortes • 23 Nov 2022
2:12
5-year update of BFORE: bosutinib vs imatinib in CML
Jorge Cortes • 23 Nov 2022
3:05
Current and future treatment strategies for blast-phase CML
Mhairi Copland • 29 Sep 2022
1:30
Key topics at ESH CML 2022
Jorge Cortes • 21 Oct 2022
View All Videos
4:23
Phase I study of olverembatinib in patients with R/R CML & Ph+ ALL
Elias Jabbour • 5 Dec 2022
2:59
OPTIC 3-year update: dose-optimization of 3 starting doses of ponatinib in CP-CML
Jorge Cortes • 23 Nov 2022
2:12
5-year update of BFORE: bosutinib vs imatinib in CML
Jorge Cortes • 23 Nov 2022
1:17
Decitabine, venetoclax and ponatinib in patients with advanced CML and Ph+ AML
Jayastu Senapati • 11 Nov 2022
View All Videos
4:23
Phase I study of olverembatinib in patients with R/R CML & Ph+ ALL
Elias Jabbour • 5 Dec 2022
2:49
Outcomes of patients with CML-CP treated with ponatinib vs 2G-TKIs in the third-line setting
Elias Jabbour • 5 Dec 2022
2:32
Outcomes of patients with CML with no molecular response within two years of TKI therapy
Aram Bidikian • 9 Jan 2023
2:59
OPTIC 3-year update: dose-optimization of 3 starting doses of ponatinib in CP-CML
Jorge Cortes • 23 Nov 2022
View All Videos
1:09
Kinase domain mutation screening in patients with Ph+ ALL and CML
Josep-Maria Ribera • 8 Oct 2022
1:49
The use of miRNAs as predictive biomarkers in CML
Andrew Wu • 22 Oct 2022
0:40
The impact of ACA in CML & the importance of monitoring these patients
Susanne Saussele • 22 Oct 2022
4:27
CML management in resource limited countries
Jerald P. Radich • 23 Aug 2020
View All Videos
3:05
The role of the immune microenvironment in CML and its impact on patient response to therapy
Aram Bidikian • 9 Jan 2023
2:59
OPTIC 3-year update: dose-optimization of 3 starting doses of ponatinib in CP-CML
Jorge Cortes • 23 Nov 2022
2:45
Understanding the cause of TKI resistance to improve management strategies in CML
Jeffrey Lipton • 26 Oct 2022
6:22
Efficacy & tolerability of available TKI therapies in CML & managing TKI resistance
Jeffrey Lipton • 26 Oct 2022
View All Videos
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals